Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases
Open accessThe DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Virus-like particles (VLPs) are nanostructures that possess diverse applications in therapeutics, immunization, and diagnostics. With the recent advancements in biomedical engineering technologies, commercially available VLP-based vaccines are being extensively used to combat infectious diseases, whereas many more are in different stages of development in clinical studies. Because of their desired characteristics in terms of efficacy, safety, and diversity, VLP-based approaches might become more recurrent in the years to come. However, some production and fabrication challenges must be addressed before VLP-based approaches can be widely used in therapeutics. This review offers insight into the recent VLP-based vaccines development, with an emphasis on their characteristics, expression systems, and potential applicability as ideal candidates to combat emerging virulent pathogens. Finally, the potential of VLP-based vaccine as viable and efficient immunizing agents to induce immunity against virulent infectious agents, including, SARS-CoV-2 and protein nanoparticle-based vaccines has been elaborated. Thus, VLP vaccines may serve as an effective alternative to conventional vaccine strategies in combating emerging infectious diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
Heath, P. T., Galiza, E. P., Baxter, D. N., Boffito, M., Browne, D., Burns, F., Chadwick, D. R., Clark, R., Cosgrove, C., Galloway, J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107659 · Cited by 1,085
Efficacy of NVX-CoV2373 Covid-19 Vaccine against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103055 · Cited by 625
Preliminary Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
Shinde, V., Bhikha, S., Hoosain, Z., Archary, M., Bhorat, Q., Fairlie, L., Lalloo, U., Masilela, M. S. L., Moodley, D., Hanley, S., et al. (2021) · doi:10.1101/2021.02.25.21252477 · Cited by 625
Walls, A. C., Fiala, B., Schäfer, A., Wrenn, S., Pham, M. N., Murphy, M., Tse, L. V., Shehata, L., O’Connor, M. A., Chen, C., et al. (2020) · Cell · doi:10.1016/j.cell.2020.10.043 · Cited by 532
The race for coronavirus vaccines: a graphical guide
Callaway, E. (2020) · Nature · doi:10.1038/d41586-020-01221-y · Cited by 492
Viral Nanoparticles for Drug Delivery, Imaging, Immunotherapy, and Theranostic Applications
Chung, Y. H., Cai, H., & Steinmetz, N. F. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.06.024 · Cited by 391
Maurer, P., Jennings, G. T., Willers, J., Rohner, F., Lindman, Y., Roubicek, K., Renner, W. A., Müller, P., & Bachmann, M. F. (2005) · European Journal of Immunology · doi:10.1002/eji.200526285 · Cited by 279
Current challenges in biotherapeutic particles manufacturing
Moleirinho, M. G., Silva, R. J. S., Alves, P. M., Carrondo, M. J. T., & Peixoto, C. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2020.1693541 · Cited by 123 · cited 1×
“…viral nucleocapsid proteins is primarily responsible for the formation of these VLPs. Non-enveloped VLPs are still being investigated as preferable candidates for developing subunit vaccines against several pathogenic diseases as they are easier to produce and purify (Naskalska and Pyrć, 2015).”
BackgroundLet’s talk about lipid nanoparticles
(2021) · Nature Reviews Materials · doi:10.1038/s41578-021-00281-4 · Cited by 119
Metadata
- Authors
- Tariq, H., Batool, S., Asif, S., Ali, M., & Abbasi, B. H.
- Venue
- Frontiers in Microbiology
- Publisher
- Frontiers Media SA
- Published
- 2022-01-03
- Volume
- 12
- Pages
- 790121-790121
- ISSN
- 1664-302X (ISSN-L)
- OpenAlex
- W4205532704
- Cited by
- 248
- References
- 9
- FWCI
- 14.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. https://app.cochat.ai/papers/10.3389/fmicb.2021.790121
- The paper
- Tariq, H., Batool, S., Asif, S., Ali, M., & Abbasi, B. H. (2022). Virus-Like Particles: Revolutionary Platforms for Developing Vaccines Against Emerging Infectious Diseases. Frontiers in Microbiology. https://doi.org/10.3389/fmicb.2021.790121
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.